Reset filter
Palavras-chave
ХИМИОТЕРАПИЯ ВСПОМОГАТЕЛЬНАЯ ×
Mostrar mais Palavras-chave
Índice
  1. 1. Estudo clínico
  2. 2. Documentação de rotina
  3. 3. Estudos de registo/coortes
  4. 4. Garantia da qualidade
  5. 5. Padrão de dados
  6. 6. Questionário do paciente
  7. 7. Especialidade médica
Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

63 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

Visit 16 GIMEMA CML0408 NCT00769327 - Visit 16

- 20/09/2021 - 1 Formulário, 11 Grupos de itens, 117 Elementos de dados, 2 Idiomas
Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, FISH (from bone marrow blood), Molecular Biology (peripheral blood), FISH (peripheral blood)
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 16 Form

Visit 13 GIMEMA CML0408 NCT00769327 - Visit 13

- 20/09/2021 - 1 Formulário, 5 Grupos de itens, 56 Elementos de dados, 2 Idiomas
Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Molecular Biology (peripheral blood)
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 13 Form

Visit 5 GIMEMA CML0408 NCT00769327 - Visit 5

- 20/09/2021 - 1 Formulário, 4 Grupos de itens, 44 Elementos de dados, 2 Idiomas
Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 5 Form

Visit 7 GIMEMA CML0408 NCT00769327 - Visit 7

- 20/09/2021 - 1 Formulário, 13 Grupos de itens, 127 Elementos de dados, 2 Idiomas
Grupos de itens: Physical Examination, Complete Blood Count, Biochemistry, Electrocardiogram, Echocardiogram, Biopsie, Preservation of cellular samples, Cytogenetics, NILOTINIB, FISH (from bone marrow blood), IMATINIB, Molecular Biology (peripheral blood), FISH (peripheral blood)
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 7 Form

Visit 3 GIMEMA CML0408 NCT00769327 - Visit 3

- 20/09/2021 - 1 Formulário, 5 Grupos de itens, 49 Elementos de dados, 2 Idiomas
Grupos de itens: Physical Examination, Complete Blood Count, NILOTINIB, Biochemistry, Electrocardiogram
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Visit 3 Form

Visit 0 GIMEMA CML0408 NCT00769327 - Visit 0

- 20/09/2021 - 1 Formulário, 4 Grupos de itens, 55 Elementos de dados, 2 Idiomas
Grupos de itens: Enrollment, Symptoms, Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 0 form.

CHOP chemotherapy regimen PETAL Study NCT00554164 - CHOP chemotherapy regimen

- 20/09/2021 - 1 Formulário, 17 Grupos de itens, 83 Elementos de dados, 2 Idiomas
Grupos de itens: Patient demographics, Therapy, Chemotherapy Regimen, Intrathecal therapy, Supportive therapy, Administration of medication, Comorbidity at the therapy begin, Medication duration, G-CSF, Cycle duration, Therapy discontinuation, Stem Cell Mobilization, Lab results prior to chemotherapy cycle, Lab results during interval after chemotherapy cycle, Toxicity, Intercurrent disease, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

(R)-ESHAP PETAL Study NCT00554164 - (R)-ESHAP

- 20/09/2021 - 1 Formulário, 17 Grupos de itens, 84 Elementos de dados, 2 Idiomas
Grupos de itens: Patient demographics, Therapy, Chemotherapy Regimen, Intrathecal therapy, Supportive therapy, Administration of medication, Comorbidity at the therapy begin, Medication duration, G-CSF, Cycle duration, Therapy discontinuation, Stem Cell Mobilization, Lab results prior to chemotherapy cycle, Lab results during interval after chemotherapy cycle, Toxicity, Intercurrent disease, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

(R)-DHAP PETAL Study NCT00554164 - (R)-DHAP

- 20/09/2021 - 1 Formulário, 17 Grupos de itens, 83 Elementos de dados, 2 Idiomas
Grupos de itens: Patient demographics, Therapy, Chemotherapy Regimen, Intrathecal therapy, Supportive therapy, Administration of medication, Comorbidity at the therapy begin, Medication duration, G-CSF, Cycle duration, Therapy discontinuation, Stem Cell Mobilization, Lab results prior to chemotherapy cycle, Lab results during interval after chemotherapy cycle, Toxicity, Intercurrent disease, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

Pre-phase Therapy PETAL Study NCT00554164 - Pre-phase Therapy

- 20/09/2021 - 1 Formulário, 10 Grupos de itens, 41 Elementos de dados, 2 Idiomas
Grupos de itens: Patient demographics, Therapy, Chemotherapy Regimen, Intrathecal therapy, Supportive therapy, Administration of medication, Comorbidity at the therapy begin, Medication duration, Intercurrent disease, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

Effect of casoptiant on cardiac conduction as compared to placebo and moxifloxacin 103447 - Eligibility Question

- 17/09/2021 - 1 Formulário, 4 Grupos de itens, 26 Elementos de dados, 1 Idioma
Grupos de itens: Administrative, Eligibility Question, Inclusion Criteria, Exclusion Criteria
Study ID: 103447 Clinical Study ID: NKV103447 Study Title:A study to evaluate the effect of casoptiant on cardiac conduction as assessed by 12-lead electrocardiogram as compared to placebo and moxifloxacin Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: casopitant Trade Name: Rezonic,Zunrisa; Zunrisa,Rezonic Study Indication: Nausea and Vomiting, Chemotherapy-Induced

PRIOR TREATMENT FOR BREAST CANCER (ADJUVANT SETTING) Roche H0650g Breast Cancer - PRIOR TREATMENT FOR BREAST CANCER (ADJUVANT SETTING)

- 15/03/2021 - 1 Formulário, 3 Grupos de itens, 18 Elementos de dados, 1 Idioma
Grupos de itens: Chemotherapy, Therapeutic regimen, ADJUVANT THERAPY
Study part: Prior treatment for breast cancer (Adjuvant setting). A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial